Indian J. Applied & Pure Bio. Vol. 41(3), 1783-1790 (2026). **ISSN: 0970-2091**

The Lipid-Redox Axis in Sarcopenic Obesity: Crosstalk, Mechanisms, and Therapeutic Opportunities

Smita Milind Chatrabhuji[1] and Vaidehi Vinay Raole[2*]

[1,2*]Department of Kriya Sharir, Parul Institute of Ayurved, Parul University, Vadodara - 391760 (India)
***Corresponding Author Email ID:** vaidehi.raole@paruluniversity.ac.in

Abstract

Sarcopenic obesity (SO), the specific co-occurrence of skeletal muscle atrophy and excess adiposity, represents a unique and escalating health challenge. This review elucidates the intricate mechanistic "crosstalk" between dysfunctional adipose tissue and skeletal muscle, identifying mitochondrial redox signaling as the central integrator.

We critically examine how the "Lipid-Redox Axis" drives muscle wasting. We detail how adipocyte-derived inflammatory cytokines (TNF-alpha, IL-6) and lipotoxic intermediates (ceramides) synergistically amplify mitochondrial reactive oxygen species (ROS) production in myocytes. This oxidative surge triggers a pathogenic cascade: (1) suppression of the NRF2/Keap1 antioxidant defense system; (2) oxidative modification of Drp1 (S-nitrosylation) promoting mitochondrial fission; and (3) activation of the NLRP3 inflammasome.

SO is a disease of organelle dysfunction. Therapeutic strategies targeting mitochondrial quality control—including mitochondria-targeted antioxidants and molecularly valid traditional phytomedicines (Rasayanas)—offer the most promising avenue. Future protocols must integrate these interventions with precision, accounting for potential pharmacokinetic interactions.

Key words : Sarcopenic Obesity, Mitochondrial Dysfunction, NLRP3, NRF2, GDF-15, Lipotoxicity, Ayurveda, Rasayana.

The demographic shift toward an aging global population has brought to the forefront two major metabolic epidemics: sarcopenia and obesity. The intersection of these conditions—Sarcopenic Obesity (SO)—creates a synergistic pathophysiology. Epidemiological data indicates that the prevalence of SO is rising alarmingly[9].

[1]PG Scholar, [2*]Professor

Clinically, individuals with SO exhibit an "obesity paradox" where high body mass index (BMI) masks profound muscle weakness, leading to a 2-fold increase in all-cause mortality.

The core question in SO research is: *Why does the accumulation of fat mass specifically precipitate the degradation of lean mass?* Emerging evidence indicates that this is not merely a physical burden but an active molecular assault. This review posits that the "Inter-Organ Crosstalk" between adipose tissue and skeletal muscle is mediated by a specific biochemical currency: Oxidative Stress (Figure 1).

The Redox Threshold: Signal vs. Damage:

To understand the pathology, one must first appreciate the physiology. Under basal conditions, low levels of mitochondrial ROS act as essential signaling molecules ("mitohormesis"), promoting adaptation. However, in SO, the chronic influx of lipids pushes the redox status beyond a critical "Redox Threshold." This shift transforms ROS from a signal into a damaging agent that overrides the cell's antioxidant capacity.

The Adipose-Muscle Axis: A Toxic Conversation:

The progression to SO is driven by the pathological remodeling of adipose tissue and its invasion of the muscle compartment (Figure 1).

Adipose Tissue Remodeling: The Inflammatory Trigger :

In the obese state, visceral adipose tissue expands rapidly causing local hypoxia. This triggers a macrophage switch from the anti-inflammatory M2 phenotype to the pro-inflammatory M1 phenotype[7]. These M1 macrophages secrete TNF-alpha and IL-6, creating a state of chronic "Meta-inflammation." A critical driver of this systemic inflammaging is gut-derived Lipopolysaccharide (LPS), which leaks into circulation ("metabolic endotoxemia") due to obesity-induced gut barrier permeability, directly activating Toll-like Receptor 4 (TLR4) on muscle cells[17,19].

Ectopic Fat and Myosteatosis :

Simultaneously, Free Fatty Acids (FFAs) "spill over" and are deposited ectopically within skeletal muscle (Myosteatosis). In SO, the downregulation of Perilipin 5 (PLIN5) disrupts the sequestration of fatty acids into neutral lipid droplets. This leads to the accumulation of toxic intermediates like Ceramides and Diacylglycerol (DAG)[4,8]. This state of "Lipotoxicity" is the primary insult that destabilizes the mitochondrial membrane.

Sexual Dimorphism in Mitochondrial Redox Control :

A critical factor in SO is biological sex. Estrogen (17beta-estradiol) acts as a mitochondrial protectant by upregulating NRF2 and PGC-1alpha[10]. Mechanistically, estrogen receptors (ER-alpha) directly induce the transcription of antioxidant enzymes[20]. The precipitous drop in estrogen during menopause removes this shield, making post-menopausal women uniquely susceptible to ROS-induced muscle wasting compared to age-matched men.



Figure 1. The Lipid-Redox Axis

Schematic illustration of the crosstalk between hypertrophic visceral adipose tissue and skeletal muscle. Key events include the secretion of TNF-alpha by M1 macrophages and the "spillover" of Free Fatty Acids (FFAs). This leads to Ceramide accumulation (Lipotoxicity), which is the primary driver of mitochondrial dysfunction.



Figure 2. Molecular Mechanisms

Detailed signaling pathway showing: (A) ETC overload generating Superoxide; (B) ROS-induced Drp1 phosphorylation (Ser616) driving fission; (C) mtDNA leakage into the cytosol activating the NLRP3 inflammasome; and (D) FoxO3a-mediated transcription of Atrogin-1.

Table-1. Molecular Targets of Therapeutic Interventions in Sarcopenic Obesity

Intervention Category	Specific Agent	Molecular Target	Mechanism of Action	Key Outcome
Mitochondrial Antioxidants	MitoQ / SkQ1	Superoxide (Matrix)	Selectively accumulates in mitochondria to scavenge ROS at the source.	Preserved membrane potential; prevents lipotoxicity.
Nutritional Pharmacology	Resveratrol	SIRT1 / PGC-1alpha	Enhances mitochondrial biogenesis and mimics exercise signaling.	Increases muscle fiber area; improved exercise adaptation.
	Sulforaphane	NRF2	Disrupts Keap1-NRF2 binding to release nuclear NRF2.	Upregulates endogenous antioxidant enzymes (HO-1, SOD).
Ayurvedic Rasayanas	Ashwagandha	Mitophagy / Drp1	Modulates mitochondrial quality control and reduces inflammation.	Increases muscle strength (1-RM) and hypertrophy.
	Amalaki	NRF2 Pathway	Potent NRF2 agonist (Hydrolysable Tannins).	Superior cellular protection compared to isolated Vitamin C.
	Curcumin	NLRP3 / NF-kB	Inhibits inflammasome assembly and cytokine release.	Breaks the inflammation-atrophy feedback loop.

Molecular Mechanisms of Mitochondrial Dysfunction :

Mitochondria are the primary site of ROS generation. In SO, the "Lipid-Redox" environment induces catastrophic failure at multiple levels (Figure 2).

Bioenergetic Failure and the ETC Bottleneck :

The massive influx of palmitate overloads the Electron Transport Chain (ETC), specifically at Compounds I and III. This forces electrons to leak, forming Superoxide (O^{2-}). These radicals specifically attack Cardiolipin, the "glue" of the inner mitochondrial membrane, exacerbating electron leak.

Disrupted Mitochondrial Dynamics: The Role of Drp1 :

Mitochondrial health relies on a balance between Fusion (Mfn1/2) and Fission

(Drp1). In SO, oxidative stress leads to the phosphorylation of Drp1 at Ser616, promoting its translocation to the mitochondria. This drives widespread fragmentation, leaving the muscle cell filled with bioenergetically incompetent organelles[11].

Activation of the NLRP3 Inflammasome:

Mitochondrial DNA (mtDNA) released from damaged organelles acts as a DAMP. Cytosolic mtDNA activates the NLRP3 Inflammasome, which cleaves pro-IL-1beta into active IL-1beta[23]. Thus, the muscle cell transitions from a victim of inflammation to a *generator* of inflammation.

Redox Control of Protein Degradation:

The loss of muscle protein is orchestrated by redox-sensitive transcription factors.

The NRF2/Keap1 Axis: A Broken Shield:

NRF2 is the master antioxidant regulator, normally tethered by Keap1. in SO, inflammation upregulates Keap1, "trapping" NRF2 in the cytoplasm. Without nuclear NRF2, the muscle fails to transcribe protective genes (HO-1, SOD), leaving contractile proteins undefended[12].

FoxO3a and the Atrogene Program :

Conversely, ROS promotes the nuclear accumulation of FoxO3a. This upregulates Atrogin-1 and MuRF1 (E3 ubiquitin ligases), which specifically tag sarcomeric proteins for destruction.

Therapeutic Frontiers: From Molecules to Validated Tradition :

Targeting "Mitochondrial Health" is the future of SO management. This involves a fusion of cutting-edge pharmacology and scientifically validated traditional efficacy.

Mitochondria-Targeted Antioxidants (MTAs):

MitoQ and SkQ1 are "smart" molecules conjugated to lipophilic cations (TPP+). They accumulate 1000-fold inside the mitochondrial matrix, scavenging superoxide *at the source*[14].

Nutritional Pharmacology and Dosing :

- Resveratrol: Activates SIRT1. Clinical trials involving 500 mg/day have demonstrated enhanced exercise adaptations and preserved muscle fiber area in older adults[2,18]. *Clinical indication:* Optimal scavenging observed at 500–1000 mg/day.
- Anthocyanins: Disrupt Keap1-NRF2 interaction. *Clinical indication:* Efficacy noted at ~320 mg/day.
- Sulforaphane: Potent NRF2 activator. Clinical data supports its efficacy in reducing oxidative biomarkers at 60 mg/day[5]. *Clinical indication:* 60 mg/day.

Phytochemical Modulators of Mitochondrial Quality Control: Reverse Pharmacology of Rasayanas :

Ayurveda, the comprehensive medical system of India, describes a class of phytomedicines known as Rasayanas (Rejuvenators). Modern "Reverse Pharmacology" has successfully mapped these empirically observed formulations to specific "Mitochondrial Adaptogen" targets.

- ***Ashwagandha (Withania somnifera):***

Randomized controlled trials have confirmed that supplementation (300 mg twice daily) significantly increases muscle strength (1-RM) and size[3,24]. Mechanistically, bioactive withanolides induce Mitophagy and improve bioenergetics[22].

- ***Amalaki (Emblica officinalis):*** As one of the richest sources of hydrolysable tannins, it acts as a potent NRF2 agonist, enhancing the endogenous antioxidant defense more effectively than isolated Vitamin C [21].
- ***Haridra (Curcuma longa):*** Extensive evidence confirms its ability to block NF-kB activation and suppress the NLRP3 inflammasome[1], directly breaking the inflammation-atrophy link.

Integrating these "Mitochondrial Adaptogens" into clinical protocols represents a scientifically grounded evolution of "Redox Medicine."

Exercise: Specificity Matters :

- HIIT: Targets Mitochondrial Quality (AMPK). High-intensity interval training has been shown to be superior to resistance training alone for stimulating mitochondrial biogenesis[15].
- Recommendation: Concurrent training is mandatory.

Translational Diagnostics & Safety :

To translate these mechanisms, we must employ sensitive biomarkers. GDF-15 acts as a specific "mitokine" sentinel, correlating with mitochondrial stress intensity in sarcopenia[6, 16,25]. Additionally, F2-Isoprostanes remain the gold standard for quantifying systemic oxidative burden[13]. Clinical protocols must rigorously evaluate Pharmacokinetic Interactions between prescribed antioxidants and phytomedicines to ensure synergistic efficacy.

Sarcopenic obesity is a multi-system failure rooted in the "Lipid-Redox Axis." Future therapies must embrace a pluralistic approach: combining precision Mico-Medicine with molecularly valid Rasayanas, guided by biomarkers like GDF-15. This integrative strategy offers the robust defense needed to preserve muscle health in an obesogenic world.

References :

1. Aggarwal, B.B., *et al*. (2020) *British Journal of Pharmacology*, *169*(8): 1672–1692.
2. Alway, S.E., *et al.* (2017). *Journal of Gerontology Series A*, *72*(12): 1595–1606.
3. Bonilla, D.A., *et al*. (2021). *Journal of Functional Morphology and Kinesiology*, *6*(1): 20.
4. Bosma, M., *et al.* (2012). *Diabetes*, *61*(11): 2679-2690.
5. Cipolla, B.G., *et al*. (2015). *Cancer Prevention Research*, *8*(8): 712-719.
6. Conte, M., *et al.* (2024). *Ageing Research Reviews*, *88:* 101952.
7. Cremonini, E., *et al*. (2025). *Redox Experimental Medicine*, (1), R1-R15.
8. Gemmink, A., *et al.* (2017). *Journal of Lipid Research*, *58:* 1421-1428.
9. Gonzalez, F., *et al.* (2025). *Aging Cell*, *24*(2): e14001.
10. Klinge, C.M. (2020). *Current Opinion in Physiology*, *15:* 1-6.
11. Liesa, M. and O.S. Shirihai, (2013). *Cell Metabolism*, *17*(4): 491-506.
12. Lindholm, M.E., *et al.* (2022). *Journal*

of Clinical Investigation, *132*(5): e14890.
13. Milne, G.L., *et al*. (2015). *Clinica Chimica Acta*, *440:* 48-56.
14. Murphy, M.P. and R.C. Hartley, (2018). *Nature Reviews Drug Discovery*, *17*(12): 865-886.
15. O'Keefe, J.H., *et al.* (2020). *Mayo Clinic Proceedings*, *95*(12): 2743-2755.
16. Ost, M., *et al*. (2025). *Redox Experimental Medicine*, *2 :* R30-R45.
17. Picca, A. and R. Calvani, (2021). *Current Opinion in Clinical Nutrition*, *24*(1): 34-40.
18. Pollack, R.M., *et al.* (2021). *Experimental Gerontology*, *154:* 111531.
19. Ticnesi, L., *et al.* (2017). *Nutrients*, *9*(10): 1120.
20. Valencia, A.P., *et al*. (2016). *Journal of Applied Physiology*, *120*(11): 1269-1278.
21. Variya, B.C., *et al*. (2020). *Pharmacological Research*, *111:* 180-200.
22. Vaughn, A., *et al.* (2024). *Aging (Albany NY)*, *16*(5): 4500-4515.
23. Wang, H., *et al.* (2017). *Science Immunology*, *2*(16): eaam9381.
24. Wankhede, S., *et al.* (2015). *Journal of the International Society of Sports Nutrition*, *12:* 43.
25. Yuan, L., *et al.* (2025). *Aging Cell*, *24*(1): e13998.